Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer.
CD8+ TIL
Colorectal cancer
cGAS-STING
dMMR/MSI
pMMR/MSS
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
21
12
2021
accepted:
30
03
2022
pubmed:
17
4
2022
medline:
1
10
2022
entrez:
16
4
2022
Statut:
ppublish
Résumé
Deficient mismatch repair (dMMR)/microsatellite instability (MSI) colorectal cancer (CRC) has high immunogenicity and better prognosis compared with proficient MMR (pMMR)/microsatellite stable (MSS) CRC. Although the activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway has been considered to contribute to the high number of CD8
Identifiants
pubmed: 35429245
doi: 10.1007/s00262-022-03200-w
pii: 10.1007/s00262-022-03200-w
doi:
Substances chimiques
Chemotactic Factors
0
Membrane Proteins
0
STING1 protein, human
0
Interferons
9008-11-1
Nucleotidyltransferases
EC 2.7.7.-
cGAS protein, human
EC 2.7.7.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2765-2776Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70:145–164. https://doi.org/10.3322/caac.21601
doi: 10.3322/caac.21601
pubmed: 32133645
Keum N, Giovannucci E (2019) Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 16:713–732. https://doi.org/10.1038/s41575-019-0189-8
doi: 10.1038/s41575-019-0189-8
pubmed: 31455888
Xie YH, Chen YX, Fang JY (2020) Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 5:22. https://doi.org/10.1038/s41392-020-0116-z
doi: 10.1038/s41392-020-0116-z
pubmed: 32296018
pmcid: 7082344
Tutlewska K, Lubinski J, Kurzawski G (2013) Germline deletions in the EPCAM gene as a cause of Lynch syndrome - literature review. Hered Cancer Clin Pract 11:9. https://doi.org/10.1186/1897-4287-11-9
doi: 10.1186/1897-4287-11-9
pubmed: 23938213
pmcid: 3765447
Kuiper RP, Vissers LE, Venkatachalam R et al (2011) Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 32:407–414. https://doi.org/10.1002/humu.21446
doi: 10.1002/humu.21446
pubmed: 21309036
Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G (2021) Mechanisms of immune escape and resistance to checkpoint inhibitor therapies in mismatch repair deficient metastatic colorectal cancers. Cancers (Basel). https://doi.org/10.3390/cancers13112638
doi: 10.3390/cancers13112638
Randrian V, Evrard C, Tougeron D (2021) Microsatellite instability in colorectal cancers: carcinogenesis, neo-antigens immuno-resistance and emerging therapies. Cancers (Basel). https://doi.org/10.3390/cancers13123063
doi: 10.3390/cancers13123063
pmcid: 8305049
Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138:2073-2087.e2073. https://doi.org/10.1053/j.gastro.2009.12.064
doi: 10.1053/j.gastro.2009.12.064
pubmed: 20420947
Deshpande M, Romanski PA, Rosenwaks Z, Gerhardt J (2020) Gynecological cancers caused by deficient mismatch repair and microsatellite instability. Cancers (Basel) 12:3319. https://doi.org/10.3390/cancers12113319
doi: 10.3390/cancers12113319
pmcid: 7697596
Pritchard CC, Grady WM (2011) Colorectal cancer molecular biology moves into clinical practice. Gut 60:116–129. https://doi.org/10.1136/gut.2009.206250
doi: 10.1136/gut.2009.206250
pubmed: 20921207
Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S (2004) Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 91:469–475. https://doi.org/10.1002/bjs.4472
doi: 10.1002/bjs.4472
pubmed: 15048750
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr (2019) Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 16:361–375. https://doi.org/10.1038/s41575-019-0126-x
doi: 10.1038/s41575-019-0126-x
pubmed: 30886395
pmcid: 7295073
Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409–413. https://doi.org/10.1126/science.aan6733
doi: 10.1126/science.aan6733
pubmed: 28596308
pmcid: 5576142
Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ (2013) Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339:826–830. https://doi.org/10.1126/science.1229963
doi: 10.1126/science.1229963
pubmed: 23258412
Gao M, He Y, Tang H, Chen X, Liu S, Tao Y (2020) cGAS/STING: novel perspectives of the classic pathway. Mol Biomed. https://doi.org/10.1186/s43556-020-00006-z
doi: 10.1186/s43556-020-00006-z
pubmed: 35006429
pmcid: 8603984
Li T, Chen ZJ (2018) The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med 215:1287–1299. https://doi.org/10.1084/jem.20180139
doi: 10.1084/jem.20180139
pubmed: 29622565
pmcid: 5940270
Jiang M, Chen P, Wang L et al (2020) cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol 13:81. https://doi.org/10.1186/s13045-020-00916-z
doi: 10.1186/s13045-020-00916-z
pubmed: 32571374
pmcid: 7310007
Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz H-J (2018) CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation–a target for novel cancer therapy. Cancer Treat Rev 63:40–47. https://doi.org/10.1016/j.ctrv.2017.11.007
doi: 10.1016/j.ctrv.2017.11.007
pubmed: 29207310
Sokolowska O, Nowis D (2018) STING signaling in cancer cells: Important or not? Arch Immunol Ther Exp (Warsz) 66:125–132. https://doi.org/10.1007/s00005-017-0481-7
doi: 10.1007/s00005-017-0481-7
Song S, Peng P, Tang Z et al (2017) Decreased expression of STING predicts poor prognosis in patients with gastric cancer. Sci Rep 7:39858. https://doi.org/10.1038/srep39858
doi: 10.1038/srep39858
pubmed: 28176788
pmcid: 5296877
Chon HJ, Kim H, Noh JH et al (2019) STING signaling is a potential immunotherapeutic target in colorectal cancer. J Cancer 10:4932–4938. https://doi.org/10.7150/jca.32806
doi: 10.7150/jca.32806
pubmed: 31598165
pmcid: 6775531
Bu Y, Liu F, Jia Q-A, Yu S-N (2016) Decreased expression of TMEM173 predicts poor prognosis in patients with hepatocellular carcinoma. PLoS One 11:e0165681. https://doi.org/10.1371/journal.pone.0165681
doi: 10.1371/journal.pone.0165681
pubmed: 27814372
pmcid: 5096716
Xia T, Konno H, Ahn J, Barber GN (2016) Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep 14:282–297. https://doi.org/10.1016/j.celrep.2015.12.029
doi: 10.1016/j.celrep.2015.12.029
pubmed: 26748708
Bakhoum SF, Cantley LC (2018) The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell 174:1347–1360. https://doi.org/10.1016/j.cell.2018.08.027
doi: 10.1016/j.cell.2018.08.027
pubmed: 30193109
pmcid: 6136429
de la Chapelle A, Hampel H (2010) Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28:3380–3387. https://doi.org/10.1200/jco.2009.27.0652
doi: 10.1200/jco.2009.27.0652
pubmed: 20516444
pmcid: 2903331
Dou Z, Ghosh K, Vizioli MG et al (2017) Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 550:402–406. https://doi.org/10.1038/nature24050
doi: 10.1038/nature24050
pubmed: 28976970
pmcid: 5850938
Santaguida S, Richardson A, Iyer DR et al (2017) Chromosome mis-segregation generates cell-cycle-arrested cells with complex karyotypes that are eliminated by the immune system. Dev Cell 41:638-651.e635. https://doi.org/10.1016/j.devcel.2017.05.022
doi: 10.1016/j.devcel.2017.05.022
pubmed: 28633018
pmcid: 5536848
Lu C, Guan J, Lu S et al (2021) DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity. Cancer Cell 39(96–108):e106. https://doi.org/10.1016/j.ccell.2020.11.006
doi: 10.1016/j.ccell.2020.11.006
Guan J, Lu C, Jin Q et al (2021) MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway. Cancer Cell 39(109–121):e105. https://doi.org/10.1016/j.ccell.2020.11.004
doi: 10.1016/j.ccell.2020.11.004
Mowat C, Mosley SR, Namdar A, Schiller D, Baker K (2021) Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN–driven CCL5 and CXCL10. J Exp Med. https://doi.org/10.1084/jem.20210108
doi: 10.1084/jem.20210108
pubmed: 34297038
pmcid: 8313406
Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. https://doi.org/10.1126/scisignal.2004088
doi: 10.1126/scisignal.2004088
pubmed: 24170934
pmcid: 3969021
Davoli T, Uno H, Wooten EC, Elledge SJ (2017) Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. https://doi.org/10.1126/science.aaf8399
doi: 10.1126/science.aaf8399
pubmed: 28104840
pmcid: 5592794
Zhang C, Li J, Wang H, Song SW (2016) Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference. Oncotarget 7:73971–73983. https://doi.org/10.18632/oncotarget.12605
doi: 10.18632/oncotarget.12605
pubmed: 27738332
pmcid: 5342028
Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550. https://doi.org/10.1016/s0140-6736(15)01281-7
doi: 10.1016/s0140-6736(15)01281-7
pubmed: 26712084
Kikuchi T, Mimura K, Okayama H et al (2019) A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ. Oncol Lett 18:5977–5985. https://doi.org/10.3892/ol.2019.10953
doi: 10.3892/ol.2019.10953
pubmed: 31788072
pmcid: 6865144
Noda M, Okayama H, Tachibana K et al (2018) glycosyltransferase gene expression identifies a poor prognostic colorectal cancer subtype associated with mismatch repair deficiency and incomplete glycan synthesis. Clin Cancer Res 24:4468–4481. https://doi.org/10.1158/1078-0432.ccr-17-3533
doi: 10.1158/1078-0432.ccr-17-3533
pubmed: 29844132
Abe T, Harashima A, Xia T, Konno H, Konno K, Morales A, Ahn J, Gutman D, Barber GN (2013) STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell 50:5–15. https://doi.org/10.1016/j.molcel.2013.01.039
doi: 10.1016/j.molcel.2013.01.039
pubmed: 23478444
Zumwalt TJ, Arnold M, Goel A, Boland CR (2015) Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. Oncotarget 6:2981–2991. https://doi.org/10.18632/oncotarget.3205
doi: 10.18632/oncotarget.3205
pubmed: 25671296
Aldinucci D, Colombatti A (2014) The inflammatory chemokine CCL5 and cancer progression. Med Inflamm 2014:292376. https://doi.org/10.1155/2014/292376
doi: 10.1155/2014/292376
Yang L, Wang B, Qin J, Zhou H, Majumdar AP, Peng F (2018) Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer. Immunopharmacol Immunotoxicol 40:91–97
doi: 10.1080/08923973.2017.1417997
Hemphill WO, Simpson SR, Liu M, Salsbury FR Jr, Hollis T, Grayson JM, Perrino FW (2021) TREX1 as a novel immunotherapeutic target. Front Immunol 12:660184. https://doi.org/10.3389/fimmu.2021.660184
doi: 10.3389/fimmu.2021.660184
pubmed: 33868310
pmcid: 8047136
Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5:834–839. https://doi.org/10.1038/ncb1038
doi: 10.1038/ncb1038
pubmed: 12942087
Konno H, Yamauchi S, Berglund A, Putney RM, Mulé JJ, Barber GN (2018) Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene 37:2037–2051. https://doi.org/10.1038/s41388-017-0120-0
doi: 10.1038/s41388-017-0120-0
pubmed: 29367762
pmcid: 6029885
Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481–485. https://doi.org/10.1038/nature09907
doi: 10.1038/nature09907
pubmed: 21478870
pmcid: 3409588
Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF (2019) STING pathway agonism as a cancer therapeutic. Immunol Rev 290:24–38. https://doi.org/10.1111/imr.12765
doi: 10.1111/imr.12765
pubmed: 31355488
pmcid: 6814203
Wilson R, Espinosa-Diez C, Kanner N et al (2016) MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nat Commun 7:13597. https://doi.org/10.1038/ncomms13597
doi: 10.1038/ncomms13597
pubmed: 27886180
pmcid: 5133658
Demaria O, De Gassart A, Coso S et al (2015) STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A 112:15408–15413. https://doi.org/10.1073/pnas.1512832112
doi: 10.1073/pnas.1512832112
pubmed: 26607445
pmcid: 4687570
Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X (2019) STING: a master regulator in the cancer-immunity cycle. Mol Cancer 18:152. https://doi.org/10.1186/s12943-019-1087-y
doi: 10.1186/s12943-019-1087-y
pubmed: 31679519
pmcid: 6827255